How a nasty, brain-eating parasite could help us fight cancer

August 26, 2016 by Hany Elsheikha, The Conversation
Meet Toxoplasma gondii. Credit: Ke Hu and John M. Murray/wikimedia, CC BY-SA

We've known since the turn of the 20th century that some infectious diseases are a major risk for developing specific cancers. More worryingly, about one-sixth of cancers worldwide are attributable to infectious agents. Globally, more than 2m cancer cases are linked to certain carcinogenic viral, bacterial or parasitic agents. Two-thirds of these occur in developing countries.

Although we've been aware of the connection between parasites and since before the 18th century, we're increasingly linking certain parasites to an increased risk of developing specific forms of cancer. For example, the fish-borne parasitic worms Opisthorchis viverrini and Clonorchis sinensis have been linked to increased risk of developing cancer of the bile duct (the tube that connects the liver to the intestines). Also, infection with the parasitic worm Schistosoma haematobium can cause bladder cancer. Worldwide, these three parasitic infections accounted for 8,300 new cancer cases in 2012.

Infections can lead to cancer by directly manipulating the genes that control growth of the affected – causing the cell to grow out of control. They can also cause cancer through long-term inflammation that leads to changes in the affected cells and in nearby immune cells or by suppressing a person's immune system that normally helps protect the body from some cancers. But we also know that the body's own immune defences can be used to fight tumour cells. And now a new study suggests that a brain-eating parasite that has been incriminated in cases of brain cancer can be reprogrammed to treat .

The team of investigators behind the new study set out to harness the immune system's reaction to the presence of the parasite Toxoplasma gondii (T. gondii), which can be found in cat faeces, as a tool to cure ovarian cancer. Specifically, they identified specific proteins secreted by T. gondii that enable the immune system to attack established ovarian tumours in mice. This involved uncovering parasite specific proteins and associated host mechanisms that are important for the development of potent antitumor responses. The researchers deleted genes for proteins that the parasite injects into a host cell to modulate cell functions and immune response during infection. They also used the genetically altered parasites to vaccinate mice with aggressive ovarian cancer.

Toxoplasma gondii tissue cyst in mouse brain. Credit: Jitinder P. Dubey

The results showed that active parasite invasion along with specific proteins secreted before and after penetration of mouse cells elicited an antitumour response and increased survival by at least 40 days (mice only live a couple of years) compared to non-vaccinated mice. While surviving a longer period with cancer can be considered as an improvement, these results should be handled carefully because vaccinated mice didn't get rid of the cancer completely and we do not know how this treatment could affect tumour regression in humans.

Terrifying bug

In the field of parasitology no single parasite is as popular as T. gondii. This single-cell parasite, which affects one third of the world's human population, is best known for its ability to invade and damage the brain and alter the behaviour of affected individuals. Long before the Zika virus became a serious concern for expectant mothers, infection with T. gondii was terrifying not only to pregnant women, but also to individuals with seriously compromised immune systems, such as HIV/AIDS patients or patients on cancer therapies. This parasite can be passed along from mothers to the fetus, putting the developing babies at risk of severe neurological and vision disorders. It is very intriguing that what used to be a disturbing infection could potentially now be the remedy for an even more terrifying disease.

The idea of turning , elicited by parasitic infection, against illnesses is not new. Some worms have been shown to lessen susceptibility to type 1 diabetes and other autoimmune and inflammatory diseases, as well as to promote wound healing. However, the potential of exploiting the immune responses associated with T. gondii to help the immune system recognise and attack ovarian cancer, which is difficult to treat, is definitely out-of-the-box thinking and deserves to be commended. The same group of investigators has previously shown that the use of attenuated T. gondii can generate longlasting immunity that protects against the recurrence of disseminated pancreatic cancer. But it is early days and much more work needs to be done to determine if a similar mechanism happens in humans.

As more is learned about the dynamic cross-talks between this parasite, cells and tumours it may be possible that T. gondii or some of its proteins can one day become a real remedy that can be used to cure ovarian cancer and hopefully other forms of cancer, too.

Explore further: Parasite proteins prompt immune system to fight off ovarian tumors in mice

Related Stories

Parasite proteins prompt immune system to fight off ovarian tumors in mice

July 22, 2016
Scientists identified the specific proteins secreted by the parasite Toxoplasma gondii that cause the immune system in mice to attack established ovarian tumors. The study, led by David Bzik of the Geisel School of Medicine ...

How Toxoplasma gondii gets noticed

January 19, 2009
Researchers provide insight into how Toxoplasma gondii, a common parasite of people and other animals, triggers an immune response in its host. The report will appear online on January 19th in The Journal of Experimental ...

New study brings long-sought vaccines for deadly parasite closer to reality

December 13, 2012
One major cause of illness from food-borne diseases is the parasite Toxoplasma gondii (T. gondii). New insights into how the immune system combats T. gondii are provided in a study published by Cell Press December 13th in ...

Toxoplasma gondii can stop cancer in its tracks as a vaccine

July 18, 2014
Toxoplasma gondii (T. gondii) is a single-celled parasite that is happiest in a cat's intestines, but it can live in any warm blooded animal. Found worldwide, T. gondii affects about one-third of the world's population, 60 ...

Increased risk from toxoplasmosis

February 25, 2015
A third of all humans carry the parasite that causes toxoplasmosis—a disease commonly associated with cats, HIV-AIDS patients and pregnant women—with scientists long believing healthy immune systems control the parasite ...

Cancer-like forms of parasites may lead to new approaches to curing diseases

November 3, 2015
A study in the Proceedings of the National Academy of Sciences shows that some forms of the single celled parasites, Trypanosoma brucei and Toxoplasma gondii behave like cancer cells.

Recommended for you

Sequencing genomes of Nigerian women could help prevent many lethal breast cancers

August 21, 2018
For the first time, DNA contributed by Sub-Saharan African women has been thoroughly evaluated with innovative genomics technology in an effort to understand the genetic bases for breast cancer in African populations.

First in-depth profile of CAR T-cell signals suggests how to improve immunotherapy

August 21, 2018
CAR T-cell therapy, which reprograms immune cells to fight cancer, has shown great promise in people with some blood cancers who have not responded to other treatments. But until now, the underlying biological pathways enabling ...

Scientists take step toward new, targeted lung cancer treatment

August 21, 2018
Scientists have identified a key molecular player in a subtype of lung cancer which could lead to a new way to tackle the disease, according to research published in Nature Communications.

New compound advances into Phase 1 trial for pancreatic cancer

August 21, 2018
A compound discovered at Sanford Burnham Prebys Medical Discovery Institute (SBP) has advanced into a Phase 1 trial for metastatic pancreatic cancer. Called CEND-1 (scientifically known as iRGD), the compound was exclusively ...

Simple test could identify bladder cancer patients who won't respond to immunotherapy

August 21, 2018
Patients who are unlikely to benefit from a commonly used immunotherapy for bladder cancer could be identified by a simple blood test, according to researchers at Brighton and Sussex Medical School (BSMS).

Annual pap test a 'thing of the past?'

August 21, 2018
The United States Preventive Services Task Force (USPSTF) has released new recommendations on screening for cervical cancer. These latest recommendations continue the trend of decreasing participant burden by lengthening ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.